Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WW domain-containing transcription regulator 1 antisense RNA 1 (WWTR1-AS1)
- Target
- WWTR1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript (NAT)
01
Overview
WW domain-containing transcription regulator 1 antisense RNA 1 (WWTR1-AS1) is a long non-coding RNA (lncRNA) located at chromosome 3q25.1, transcribed antisense to the WWTR1 gene. It is significantly overexpressed in multiple cancers, including breast cancer, head and neck squamous cell carcinoma, and cervical squamous cell carcinoma, where its expression correlates with higher tumor grade, metastasis, and worse prognosis. Functionally, WWTR1-AS1 promotes cancer cell proliferation, migration, invasion, stemness, and resistance to apoptosis, possibly via modulating the stability and expression of its sense partner WWTR1 mRNA and regulating transcriptional and signaling networks. Elevated WWTR1-AS1 can serve as a reliable diagnostic and prognostic biomarker in several cancer types, and preclinical studies suggest it may be a candidate therapeutic target, though no direct drugs are available and clinical targeting remains investigational.
- Other names
- WWTR1 antisense RNA 1 (non-protein coding)WWTR1-AS1
02
Mechanism of action
Not applicable (no drugs directly target WWTR1-AS1 as of current knowledge). Antisense oligonucleotide-mediated knockdown has functional effects in preclinical studies.
03
Biological functions
Regulation of gene expression (including modulation of mRNA stability and interactions with proteins and RNAs)Regulation of cell proliferationMigration and invasion of cancer cellsApoptosis resistanceRegulation of transcriptionRegulation of cell adhesion and signaling pathways
04
Disease associations
Cancer (including breast cancer, head and neck squamous cell carcinoma, cervical squamous cell carcinoma)OncogenesisTumor aggressiveness, metastasis, and prognosis in cancer
05
Safety considerations
No clinical therapies directly target WWTR1-AS1, so safety profile in therapeutic targeting is unknownTheoretical risk of off-target gene regulation, as with all lncRNA-directed therapies
06
Interacting drugs
None currently reported
07
Biomarkers
WWTR1-AS1 itself is a biomarker for cancer diagnosis and prognosis, especially in breast cancer and head and neck squamous cell carcinoma
Beyond the preview
Go deeper on WW domain-containing transcription regulator 1 antisense RNA 1 (WWTR1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WW domain-containing transcription regulator 1 antisense RNA 1 (WWTR1-AS1).